UPL’s arm enters into license agreement with Meiji Seika Pharma

11 May 2021 Evaluate

UPL’s subsidiary has entered into a license agreement with Japanese company, Meiji Seika Pharma for exclusive access to Flupyrimin for rice in Southeast Asia. Under the license agreement, UPL will obtain exclusive rights to develop, register and commercialize formulations of Flupyrimin for foliar applications in rice in Southeast Asia, expanding the on-going collaboration between the two companies with this compound. Together, both companies will continue their contributions to the development of differentiated solutions based on Flupyrimin to address farmer pain points and improve their livelihoods.

UPL is global player of crop protection products has customer base in 123 countries. It has subsidiary offices in Argentina, Australia, Bangladesh, Brazil, China, Canada, Denmark, Indonesia, France, Hong Kong, Japan, Korea, Mauritius, Mexico, New Zealand, Russia, Spain, Taiwan, South Africa, USA, UK, Vietnam and Zambia.

UPL Share Price

481.00 -3.60 (-0.74%)
18-Apr-2024 16:01 View Price Chart
Peers
Company Name CMP
UPL 481.00
BASF India 3620.90
PI Industries 3729.95
Bayer CropScience 5558.90
Sumitomo Chemical India 399.65
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.